Erectile dysfunction market research report
Select License Type
Please select Licence type

Single License $4000

Team License $4500

Corporate License $5000

Want to have a Sample report, before the purchase ? REQUEST SAMPLE

This market research report on the erectile dysfunction market offers analysis on market size and forecast, market share, industry trends, growth drivers, and vendor analysis. The study also includes insights on segmentation by therapy type (drug therapies and device therapies) and geography (APAC, Europe, Latin America, MEA, and North America).

Key highlights of erectile dysfunction market:

  • A high prevalence rate of conditions like benign prostate hyperplasia, diabetes, high blood pressure, and high cholesterol can lead to increase in the number of the erectile dysfunction population.
  • Another major market enabler is the significant increase in disease awareness among the people worldwide. This has propelled the volume of treatment-seeking population.
  • The medical devices industry has witnessed significant advances in device technology such as device manufacturing, the inclusion of precise and customizable product features, and other technological advances in the erectile dysfunction market.
  • The emergence of advanced drug formulations such as oral drug therapies, and topical therapies has dominated the global erectile dysfunction market.
  • Mergers and acquisitions in erectile dysfunction market will allow players to gain competitive advantage with a wide product portfolio, vast geographical reach, and increased growth and profitability.

Erectile Dysfunction Market - Overview

Increasing disease awareness, growing patient willingness to seek medical assistance for disease management, and the increasing presence of favorable guidelines are driving the growth of the erectile dysfunction market. The three most popular erectile dysfunction drugs that are available in the market are ED oral drugs, Viagra, Cialis, and Levitra. The global erectile dysfunction market is also witnessing a rising demand for low-cost generic drugs, especially in the APAC countries such as Indian and China. The US and Europe are the main revenue contributors in the global erectile dysfunction market. The growing number of chronic medical conditions such as diabetes, hypertension, dyslipidemia, and coronary heart disease across the globe is also increasing the number of erectile dysfunction patients and boosting the demand for therapeutics in the global market. The increasing investments in R&D for the development of new drugs and clinical trials will augment the growth of the erectile dysfunction market.

The growing awareness of male sexual health conditions and the increasing healthcare spending for sexual wellness, especially in the APAC region will propel the development of the erectile dysfunction market. The introduction of innovative drug therapy will have a positive impact on the growth of the erectile dysfunction market. The erectile dysfunction market is expected to generate revenue of $4.25 billion during the forecast period.

Global Erectile Dysfunction Market Size by Revenue

Erectile Dysfunction Market Size by revenue

Erectile Dysfunction Market - Dynamics

Increase in strategic agreements and consolidations among the leading vendors to expand their services or product portfolios is likely to contribute to the growth of the global erectile dysfunction market. Mergers and acquisitions will allow players to gain competitive advantage with a wide product portfolio and vast geographical reach, thereby driving the growth and profitability of vendors in the erectile dysfunction market. These strategic consolidations and mergers will help prominent companies to expand their businesses in emerging markets and widen their distribution networks to attract a large consumer base. For instance, a licensing agreement between A. Menarini Asia-Pacific and Mitsubishi Tanabe Pharma was signed to commercialize and promote avanafil in China, Hong Kong, Taiwan, Macao, the Philippines, Singapore, Indonesia, Malaysia, Thailand, and Vietnam.

Erectile Dysfunction Market Segmentation

This market research report includes a detailed segmentation of the market by therapy and geography.

Segmentation of global Erectile Dysfunction Market by Therapy Type

Erectile Dysfunction Market – By Therapy Type

Drugs therapy type to dominate the erectile dysfunction market during the forecast period

The erectile dysfunction market by therapy type is classified into drugs and devices. The drugs therapy segment dominated the erectile dysfunction market, accounting for close to 89% of the total market share in 2017 and is expected to generate revenue of about $3,487.41 million during the forecast period. Preferability for needle-free penile injection kits and increase in disease awareness will fuel the growth of this drug segment in the erectile dysfunction market. The market for other drug therapy types, topical agents, intraurethral suppositories, and intracavernosal injections is expected to grow at a moderate pace over the next few years. The erectile dysfunction market will also observe a negative growth due to the patent expiration of generic versions of key oral drugs Viagra, Cialis, and Levitra during the forecast period.

Erectile Dysfunction Market – By Geography

North America to occupy the largest market share in the erectile dysfunction market during the forecast period

The geographical segment in the erectile dysfunction market is divided into APAC, Europe, Latin America, MEA, and North America. North America dominated the global erectile dysfunction market, occupying more than 43% of the total market share in 2017 and is expected to generate the revenue of $1,832.82 million by 2023. Factors such as better access to ED treatments and reimbursement coverage for high post penile implant surgeries is fueling the growth of the erectile dysfunction market in North America. The US accounts for more than 90% of the total market share in the erectile dysfunction market in North America. The high uptake and access to both prescription and OTC devices in North America is attributing the revenue of the erectile dysfunction market in this region. Moreover, increasing penile implantation surgical procedures, growing e-commerce sales of penile erection devices, and rising preference for advanced non-invasive devices will have a positive impact on the growth of the erectile dysfunction market in North America.

Key Countries Profiled in the report are

  • US
  • Canada
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Japan
  • India
  • China
  • Australia
  • Brazil
  • Mexico

Key Vendor Analysis

The erectile dysfunction market is oligopolistic, as a limited number of major players occupies the predominant market share. A minority of the market share has occupied by a surfeit of specialty and generic drug companies. The strategic initiatives adopted by the leading and other prominent companies will intensify the competition in the erectile dysfunction market during the forecast period. The leading companies are focusing on leveraging their strengths to diversify their product portfolios and increase their global market presence. The entry of new players and the introduction of innovative therapeutics will increase the level of competition in the global erectile dysfunction market during the forecast period.

The major vendors in the global market are:

  • Bayer AG
  • Eli Lilly and Company
  • VIVUS Inc.
  • Pfizer
  • Boston Scientific Corp.
  • Coloplast A/S

Other prominent vendors include Apricus Biosciences, Inc, Endo International plc, Futura Medical, Premedon, Teva Pharmaceutical Industries Limited (Teva), Zephyr Surgical Implants (ZSI), Augusta Medical Systems LLC (Augusta Medical), Post-T-Vac Medical, Bonro Medical, Cristalia Produtos Quimicos Farmaceuticos Ltd, and SK Chemicals.

Key market insights include

  1. The analysis of erectile dysfunction market provides market size and growth rate for the forecast period 2018-2023.
  2. It offers comprehensive insights on current industry trends, trend forecast, and growth drivers about the erectile dysfunction market.
  3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
  4. It offers a complete overview of market segments and the regional outlook for erectile dysfunction market.
  5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.

The global erectile dysfunction market size is expected to reach $4.25 billion by 2023. 

The global erectile dysfunction market is driven by the wide availability of treatment options oral therapies and newly emergent low-intensity extra-corporeal shockwave therapy. The introduction of other conventional therapies such as oral, topical, penile injectables, and vacuum constriction devices will also create opportunities for vendors in the global erectile dysfunction market. The market research report provides in-depth market analysis and segmental analysis of the global erectile dysfunction market by product, distribution channel, material, and geography.

Base Year:                  2017

Forecast Year:           2018–2023

The study considers the present scenario of the global erectile dysfunction market and its market dynamics for the period 2018−2023. The study covers a detailed overview of various market growth enablers, restraints, and trends. It covers both the demand and supply sides of the market. The study also profiles and analyzes the top six leading companies and 12 other prominent companies operating in the market.

Major Vendors in the Erectile Dysfunction Market

  • Bayer AG
    • Key Financial Highlights
    • Strength Assessment
    • Strategy Assessment
    • Opportunity Assessment
  • Eli Lilly and Company
  • VIVUS Inc.
  • Pfizer
  • Boston Scientific Corp.
  • Coloplast A/S

Prominent Players in the Erectile Dysfunction Market

  • Apricus Biosciences Inc.
    • Strength Assessment
    • Strategy Assessment
    • Opportunity Assessment
  • Endo International plc
  • Futura Medical
  • Premedon
  • Teva Pharmaceutical Industries Limited (Teva)
  • Zephyr Surgical Implants (ZSI)
  • Augusta Medical Systems LLC (Augusta Medical)
  • Post-T-Vac Medical
  • Bonro Medical
  • Cristalia Produtos Quimicos Farmaceuticos Ltd.
  • SK Chemicals

Market Segmentation by Therapy Type

  • ED Drugs
    • Oral Therapies
    • Topical Therapies
    • Intrauretheral suppositories & Penile injection therapies
  • ED Devices
    • Vacuum erection devices
    • Penile Implants
    • Others

Market Segmentation by Geography

  • North America
    • US
    • Canada
  •  Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • APAC
    • Japan
    • India
    • China
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • MEA

1          Research Methodology

2          Research Objectives

3          Research Process

 

4          Report Coverage

4.1       Market Definition

4.2       Base Year

4.3       Scope of Study

4.3.1   Market Segmentation by Therapy Type

4.3.2   Market Segmentation by Geography

 

5          Report Assumptions & Caveats

5.1       Currency Conversion rate

5.2       Market Derivation

 

6          Market at a Glance

 

7          Introduction

7.1       Overview OF Penile Erection and Erectile Dysfunction

7.2       Signs and Symptoms

7.3       Classification

7.3.1   Psychogenic ED

7.3.2   Neurogenic ED

7.3.3   Vasculogenic ED

7.4       Etiology of ED

7.5       Epidemiology

 

8          Disease Diagnosis and Treatment Guidelines

8.1       Diagnosis

8.2       Initial Assessment of Medical and Sexual History

8.3       Physical Examination

8.4       Laboratory Tests

8.5       Specialized Diagnostic Tests

8.5.1   Nocturnal Penile Tumescence (NPT) and Rigidity Test

8.5.2   Intracavernous Injection Test

8.5.3   Duplex Ultrasound of Penis

8.5.4   Arteriography and Dynamic Infusion Cavernosometry

8.5.5   Psychiatric Assessment

8.6       Treatment

8.6.1   Initial Treatment Approach

8.6.2   Treatment Options for ED

 

9          Pipeline Landscape

9.1       Overview

9.2       Key Investigational Drugs/Devices

9.3       Dormant/Terminated/Withdrawn Drug Candidates

9.4       Product Profile: Pheonix

9.4.1   Overview

9.4.2   Product Profile

9.4.3   Future Outlook

9.5       Product Profile: MED2002 (Glyceryl Trinitrate (GTN))

9.5.1   Overview

9.5.2   Product Profile

9.5.3   Future Outlook

 

10        Marketed Products Landscape

10.1    Overview

10.2    Product Approval Timeline

10.3    Comparative Analysis of ED Pharmaceuticals

10.3.1 Comparative Analysis of PDE5 inhibitors

10.4    Comparative Analysis Of ED Devices

 

11        Unmet needs In Erectile Dysfunction Market

 

12        Market Dynamics

12.1    Market Growth Enablers

12.1.1 Increase in Incidence of ED and Other Related Chronic Diseases

12.1.2 Increase in Adoption of Advanced Alternative Modalities

12.1.3 Increase in Disease Awareness

12.1.4 YOY Impact of Market Enablers

12.2    Market Growth Restraints

12.2.1 Low Treatment Seeking Pool

12.2.2 Key Patent Expiries and Increased Low-cost Generics Medicines

12.2.3 Risk of Counterfeit Versions

12.2.4 YOY Impact of Market Restraints

12.3    Market Opportunities & Trends

12.3.1 Technological Advances in ED Treatment Modalities

12.3.2 Advances in ED Drug Formulations

12.3.3 Increase in Strategic Agreements and Consolidations

12.3.4 YOY Impact of Trends and Opportunities

13        Global Erectile Dysfunction Market

13.1    market Overview

13.2    Market Size & Forecast

 

14        Erectile Dysfunction Market- by Therapy Type

14.1    Segment Overview

 

15        Drug Therapy Market

15.1    Overview

15.2    Oral Therapies

15.2.1 Market Size & Forecast

15.3    Topical Therapies

15.3.1 Market Size & Forecast

15.4    Injectable and Intraurethral Suppositories

15.4.1 Market Size & Forecast

 

16        Device Therapy Market

16.1    Overview

16.2    Penile Implants

16.2.1 Market Size & Forecast

16.3    Vacuum Therapy Devices

16.3.1 Market Size & Forecast

16.4    Others Erectile Dysfunction Devices

16.4.1 Market Size & Forecast

 

17        Erectile Dysfunction Market - Geography

17.1    Market Overview

 

18        North America: Erectile Dysfunction Market

18.1    Market Overview

18.2    Market Size & Forecast

18.3    Erectile Dysfunction Drugs Market

18.3.1 Market Size & Forecast

18.4    Erectile Dysfunction Devices Market

18.4.1 Market Size & Forecast

18.5    Key Countries

18.5.1 US: Market Size & Forecast

18.5.2 Canada: Market Size & Forecast

 

19        Europe: Erectile Dysfunction Market

19.1    Market Overview

19.2    Market Size & Forecast

19.3    Erectile Dysfunction Drugs Market

19.3.1 Market Size & Forecast

19.4    Erectile Dysfunction Devices Market

19.4.1 Market Size & Forecast

19.5    Key Countries

19.5.1 Germany: Market Size & Forecast

19.5.2 UK: Market Size & Forecast

19.5.3 France: Market Size & Forecast

19.5.4 Italy: Market Size & Forecast

19.5.5 Spain: Market Size & Forecast

 

20        APAC: Erectile Dysfunction Market

20.1    Market Overview

20.2    Market Size & Forecast

20.3    Erectile Dysfunction Drugs Market

20.3.1 Market Size & Forecast

20.4    Erectile Dysfunction Devices Market

20.4.1 Market Size & Forecast

20.5    Key Countries

20.5.1 Japan: Market Size & Forecast

20.5.2 China: Market Size & Forecast

20.5.3 India: Market Size & Forecast

20.5.4 Australia: Market Size & Forecast

 

21        Latin America: Erectile Dysfunction Market

21.1    Market Overview

21.2    Market Size & Forecast

21.3    Erectile Dysfunction Drugs Market

21.3.1 Market Size & Forecast

21.4    Erectile Dysfunction Devices Market

21.4.1 Market Size & Forecast

21.5    Key Countries

21.5.1 Brazil: Market Size & Forecast

21.5.2 Mexico: Market Size & Forecast

 

22        MEA: Erectile Dysfunction Market

22.1    Market Overview

22.2    Market Size & Forecast

22.3    Erectile Dysfunction Drugs Market

22.3.1 Market Size & Forecast

22.4    Erectile Dysfunction Devices Market

22.4.1 Market Size & Forecast

 

23        Competitive Landscape

23.1    Competitive Overview: Erectile Dysfunction Drugs Segment

23.2    Competitive Overview: Erectile Dysfunction Devices Segment

23.3    Key News

23.4    Strategic Recommendations for Market Participants

 

24        Key Company Profiles

24.1    Bayer AG

24.1.1 Key Financial Highlights

24.1.2 Strength Assessment

24.1.3 Strategy Assessment

24.1.4 Opportunity Assessment

24.2    ELI LILLY and Company

24.2.1 Key Financial Highlights

24.2.2 Strength Assessment

24.2.3 Strategy Assessment

24.2.4 Opportunity Assessment

24.3    VIVUS Inc.

24.3.1 Key Financial Information

24.3.2 Strength Assessment

24.3.3 Strategy Assessment

24.3.4 Opportunity Assessment

24.4    Pfizer

24.4.1 Key Financial Highlights

24.4.2 Strength Assessment

24.4.3 Strategy Assessment

24.4.4 Opportunity Assessment

24.5    Boston Scientific Corp.

24.5.1 Key Financial Highlights

24.5.2 Strength Assessment

24.5.3 Strategy Assessment

24.5.4 Opportunity Assessment

24.6    ColoPlast A/S

24.6.1 Strength Assessment

24.6.2 Strategy Assessment

24.6.3 Opportunity Assessment

 

25        Other Prominent Companies

25.1    Apricus Biosciences INC.

25.1.1 Strength Assessment

25.1.2 Strategy Assessment

25.1.3 Opportunity Assessment

25.2    Endo International plc

25.2.1 Strength Assessment

25.2.2 Strategy Assessment

25.2.3 Opportunity Assessment

25.3    Futura MedICAL plc

25.3.1 Strength Assessment

25.3.2 Strategy Assessment

25.3.3 Opportunity Assessment

25.4    Promedon

25.4.1 Strength Assessment

25.4.2 Strategy Assessment

25.4.3 Opportunity Assessment

25.5    Teva Pharmaceuticals Ltd.

25.5.1 Strength Assessment

25.5.2 Strategy Assessment

25.5.3 Opportunity Assessment

25.6    Zephyr Surgical Implants (ZSI)

25.6.1 Strength Assessment

25.6.2 Strategy Assessment

25.6.3 Opportunity Assessment

25.7    Augusta Medical Systems LLC

25.7.1 Strength Assessment

25.7.2 Strategy Assessment

25.7.3 Opportunity Assessment

25.8    Post-T-Vac Medical

25.8.1 Strength Assessment

25.8.2 Strategy Assessment

25.8.3 Opportunity Assessment

25.9    Bonro Medical

25.9.1 Strength Assessment

25.9.2 Strategy Assessment

25.9.3 Opportunity Assessment

25.10  Cristalia Produtos Quimicos Farmaceuticos Ltda

25.10.1           Strength Assessment

25.10.2           Strategy Assessment

25.10.3           Opportunity Assessment

25.11  SK Chemicals

25.11.1           Strength Assessment

25.11.2           Strategy Assessment

25.11.3           Opportunity Assessment

 

26        Report Summary

26.1    Qualitative Summary of Global ED Market

26.2    Quantitative Summary of Erectile Dysfunction Market

 

27        Appendix

27.1    List of Abbreviations

          

List of Exhibits          

Exhibit 1         Segmentation of Global ED Market

Exhibit 2         Market Size Calculation Approach 2017

Exhibit 3         Schematic Representation of Penile Erection

Exhibit 4         Snapshot of ED Pathophysiology

Exhibit 5         Common Signs and Symptoms of Erectile Dysfunction

Exhibit 6         International Society of Impotence Research's ED Classification

Exhibit 7         Distinguishing Features of ED Sub-types

Exhibit 8         Common Causes of ED

Exhibit 9         Percent of ED Cases Caused due to Specific Conditions

Exhibit 10       ED Global Prevalence Projection 1995–2025 (Million)

Exhibit 11       Basic Diagnostic Work-up in Patients with ED

Exhibit 12       ED Treatment Algorithm

Exhibit 13       ED Product Approval Timeline

Exhibit 14       Limitations of Alternative ED Therapies

Exhibit 15       Increase in Global Diabetes Prevalence by Region 2015–2040 (Million)

Exhibit 16       ED Prevalence by Region 1995 and 2025 (Million)

Exhibit 17       Major Factors Restricting ED Treatment

Exhibit 18       Global ED Market 2017–2023 ($ million)

Exhibit 19       Global ED Market by Therapy Type

Exhibit 20       Percentage of ED Market Share by Therapy Type (2017, 2020, and 2023)

Exhibit 21       Global ED Market by Therapy Type ($ million)

Exhibit 22       Global ED Market Lucrativeness by Therapy Type

Exhibit 23       Global ED Drugs Market by Drug Type 2017–2023 ($ million)

Exhibit 24       Percentage Shares of Types of ED Drug Therapies (2017–2023)

Exhibit 25       Global Revenue of Blockbuster ED Drugs (2012–2016) ($ million)

Exhibit 26       Key Advantages and Disadvantages of Oral ED Treatments

Exhibit 27       Global Oral ED Drug Therapy Market Size and Forecast 2017–2023 ($ million)

Exhibit 28       Key Advantages and Disadvantages of Topical ED Treatments

Exhibit 29       Global Topical ED Drug Therapy Market Size and Forecast 2017–2023 ($ million)

Exhibit 30       Key Advantages and Disadvantages of Penile Injection Treatments

Exhibit 31       Key Advantages and Disadvantages of Intraurethral Suppositories

Exhibit 32       Global ED Injection and Suppository Drug Therapy Market ($ million) 2017–2023

Exhibit 33       Global ED Devices Market by Drug Type 2017–2023 ($ million)

Exhibit 34       Percentage Shares of Types of Drug Therapies 2017−2023

Exhibit 35       Key Conventionally Available Penile Implants

Exhibit 36       Key Factors Considered for Penile Implant Surgery

Exhibit 37       Key Advantages and Drawbacks of Penile Implants

Exhibit 38       Global ED Penile Implants Market Size and Forecast 2017–2023 ($ million)

Exhibit 39       Key Advantages and Drawbacks of Vacuum Constriction Devices

Exhibit 40       Global ED Vacuum Therapy Device Market Size and Forecast 2017–2023 ($ million)

Exhibit 41       Global Other ED Device Market Size and Forecast 2017–2023 ($ million)

Exhibit 42       Global ED Market by Geography

Exhibit 43       Global ED Market by Geography ($ million)

Exhibit 44       Market Revenue Growth Rates Comparison by Geography

Exhibit 45       Global ED Market Lucrativeness by Geography 2023

Exhibit 46       ED Market in North America by Country 2017

Exhibit 47       Prevalence of ED in North America

Exhibit 48       ED Market in North America 2017–2023 ($ million)

Exhibit 49       ED Drugs Market in North America 2017–2023 ($ million)

Exhibit 50       ED Devices Market in North America 2017–2023 ($ million)

Exhibit 51       ED Market in US 2017–2023 ($ million)

Exhibit 52       ED Market in Canada 2017–2023 ($ million)

Exhibit 53       ED Market in Europe by Country 2017

Exhibit 54       Prevalence Trend of Prostate Cancer Holding High Associated Risk for ED Incidence in Europe 2012–2020 (thousand)

Exhibit 55       ED Market in Europe 2017–2023 ($ million)

Exhibit 56       ED Drugs Market in Europe 2017–2023 ($ million)

Exhibit 57       ED Devices Market in Europe 2017–2023 ($ million)

Exhibit 58       Open and Transurethral Proctectomy Surgeries in Germany 2012–2015 (in ‘000’s)

Exhibit 59       ED Market in Germany 2017–2023 ($ million)

Exhibit 60       ED Market in UK 2017–2023 ($ million)

Exhibit 61       ED Market in France 2017–2023 ($ million)

Exhibit 62       ED Market in Italy 2017–2023 ($ million)

Exhibit 63       ED Market in Spain 2017−2023 ($ million)

Exhibit 64       ED Market in APAC 2017–2023 ($ million)

Exhibit 65       ED Drugs Market in APAC 2017–2023 ($ million)

Exhibit 66       ED Devices Market in APAC 2017–2023 ($ million)

Exhibit 67       ED Market in Japan 2017–2023 ($ million)

Exhibit 68       ED Market in China 2017–2023 ($ million)

Exhibit 69       ED Market in India 2017–2023 ($ million)

Exhibit 70       ED Market in Australia 2017–2023 ($ million)

Exhibit 71       ED Market in Latin America 2017–2023 ($ million)

Exhibit 72       ED Drugs Market in Latin America 2017–2023 ($ million)

Exhibit 73       ED Devices Market in Latin America 2017–2023 ($ million)

Exhibit 74       ED Market in Brazil 2017–2023 ($ million)

Exhibit 75       ED Market in Mexico 2017–2023 ($ million)

Exhibit 76       ED Market in MEA 2017–2023 ($ million)

Exhibit 77       ED Drugs Market in MEA 2017–2023 ($ million)

Exhibit 78       ED Devices Market in MEA 2017–2023 ($ million)

Exhibit 79       Leading ED Drug Vendors

Exhibit 80       Leading ED Drug Vendors

Exhibit 81       Key Vendors in ED Device Market by Product Type

Exhibit 82       Strategic Success Factors of Companies in Global ED Market

Exhibit 83       Bayer: Key Financial Highlights 2015–2016 ($ billion)

Exhibit 84       Bayer: Key Financial Highlights and Revenue by Region 2015–2016 ($ Billion)

Exhibit 85       Eli Lilly: Key Financial Highlights ($ billion)

Exhibit 86       Eli Lilly: Key Financial Highlights Revenue by Therapeutic Area 2016

Exhibit 87       Vivus: Key Financial Highlights Revenue ($ million)

Exhibit 88       Pfizer: Key Financial Highlights ($ billion)

Exhibit 89       Boston Scientific: Key Financial Highlights Revenue by Business Segment (%) (2016)

Exhibit 90       Boston Scientific: Key Financial Highlights

 

List of Tables 

Table 1            Key Geographies Definition

Table 2            Key Caveats

Table 3            Currency Conversion 2013−2017

Table 4            Common Causes of ED by Sub-Type

Table 5            Key Investigational Drugs/Devices for Treatment of ED

Table 6            Terminated/Withdrawn Drug Candidates

Table 7            PheoniX Product Profile

Table 8            MED2002 Product Profile

Table 9            Comparative analysis of key PDE5 inhibitors

Table 10         Comparative Analysis of Key ED Devices' Functionalities

Table 11         Limitations and Adverse Events Associated with PDE5 Inhibitors

Table 12         YOY Impact of Market Enablers 2017–2023

Table 13         Patent Expiry Timeline of Key ED Drugs

Table 14         YOY Impact of Market Restraints 2017–2023

Table 15         YOY Impact of Trends and Opportunities 2017–2023

Table 16         Global ED Market by Therapy Type 2017–2023 ($ million)

Table 17         Global ED Drugs Market by Therapy Type 2017–2023 ($ million)

Table 18         Patent Loss Timeline for Viagra, Cialis, and Levitra

Table 19         Global ED Devices Market by Therapy Type 2017–2023 ($ million)

Table 20         Key Commercial Penile Implants by Type

Table 21         Key Commercial Vacuum Constriction Devices

Table 22         Global ED Market by Geography 2017–2023 ($ million)

Table 23         ED Drugs Product Portfolio of Other Prominent Vendors

Table 24         Qualitative Summary of Global ED Market

Table 25         Quantitative Summary of Global ED Market by Geography ($ million)

Table 26         Quantitative Summary of Global ED Market by Geography (Revenue %)

Table 27         Quantitative Summary of Global ED Market by Therapy Type ($ million)

           

Best Trending Reports in the Market

Our focus is to incorporate advanced data derivation techniques and methodologies in market research reports. It is our endeavor to keep abreast of advanced technological developments and emerging trends to stay relevant. It helps us to maintain and improve our products and serve our customers better.

arizton upcomming Image
Apr-2019

Data Center Rack Market in Europe - Industry Outlook and Forecast 2019-2024

Number Of Pages: 236

arizton upcomming Image
Apr-2019

Fire Sprinkler System Market - Global Outlook and Forecast 2019-2024

Number Of Pages: 221

arizton upcomming Image
Apr-2019

Telehealth Market - Global Outlook and Forecast 2019-2024

Number Of Pages: 230

arizton upcomming Image
Apr-2019

Earphones and Headphones Market in US - Industry Outlook and Forecast 2019-2024

Number Of Pages: 219

arizton upcomming Image
Apr-2019

Data Center Construction Market in Europe - Industry Outlook and Forecast 2019-2024

Number Of Pages: 295

arizton upcomming Image
Mar-2019

Global Electric Lawn Mower Market – Comprehensive Study and Strategic Analysis 2019−2024

Number Of Pages: 387

PURCHASE THIS REPORT
REQUEST SAMPLE